Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A team of international collaborators including DPAG's Dr Mootaz Salman has been researching a promising new therapeutic for the treatment of strokes and other brain injuries.

Effect of TFP on brain metabolic markers after stroke. Representative images of FTIR spectroscopic imaging at 24 h post-stroke in non-treated stroke and sham animals, and animals treated with TFP at 30 minute pre- stroke or 1 h post-stroke.
FTIR spectroscopic imaging shows the effect of trifluoperazine (TFP) on brain metabolic markers after stroke

Researchers from the University of Saskatchewan, Columbia University and the University of Oxford have used synchrotron imaging, combined with traditional techniques, to assess the effects of an FDA-approved antipsychotic medication, known as trifluoperazine (TFP), during the acute phase post stroke.

With the help of the Canadian Light Source (CLS) at the University of Saskatchewan (USask) and the Stanford Synchrotron Radiation Light Source (SSRL), the team was able to measure subtle changes in the biochemistry of brain tissue – measurements that are only possible with the use of a synchrotron.

“The synchrotron at the CLS provides us with a tool that allowed us to map unprecedented levels of brain detail,” said co-first author and corresponding author Dr Mootaz Salman, DPAG Research Scientist at the Oxford Parkinson's Disease Centre and Junior Research Fellow at Wolfson College.

Already approved for human use in the treatment of schizophrenia, the team believes that TFP has the potential to stop the swelling in the brain that occurs after a stroke or other cerebral injury.

“According to the World Health Organization, around 60 million people sustained a traumatic brain or spinal cord injury and a further 15 million people suffered from a stroke in 2020,” said Dr Salman. “Edema, which is swelling due to water or other body fluid accumulation, is the hallmark of stroke and plays a major role in stroke-associated morbidity and mortality.”

USask professor and Saskatchewan Clinical Stroke Research Chair Dr Michael Kelly, says that the CLS played an important role in understanding how TFP could be used for stroke patients. “Synchroton imaging has facilitated research on effects of stroke on brain energy metabolism and elemental distribution, which has given us new insights into stroke treatment.”

Dr Salman and Dr Kelly’s team has demonstrated that a dose of TFP reduces edema in a mouse model of stroke—a breakthrough that could lead to the development of new treatment options for stroke patients.

TFP acts on doughnut-shaped water channel proteins, called aquaporins, in brain cells. During a stroke, the brain’s blood supply is restricted, which prevents cells from receiving enough oxygen. These oxygen-starved cells are unable to do their usual job of maintaining a balance of fluid, nutrients and electrolytes within the brain, leading to severe swelling.

“Water rushes from the outside through these doughnut-shaped proteins, into the cells that then swell,” Dr Salman said. “The build-up of pressure damages the fragile brain tissue, disturbing the flow of electrical signals from the brain to the body.”

TFP stops this from happening by preventing a signal that would normally cause more aquaporin channels to rise to the surface of brain cells. Other treatments — which often include invasive surgeries — are techniques used to manage symptoms and minimize damage that has already occurred.

TFP is already a licensed medicine, Dr Salman says it could be rapidly repurposed for use in new therapeutic protocols for stroke during the early acute phase.

“Our novel approach offers new hope for patients with central nervous system injuries and strokes and has a huge therapeutic potential. These findings suggest it could be a good candidate for early phase of human clinical application at a low treatment cost in the near future,” Dr Salman said.

Story by Erin Matthews on the Canadian Light Source website.

The full paper "The effects of trifluoperazine on brain edema, aquaporin-4 expression and metabolic markers during the acute phase of stroke using photothrombotic mouse model" is available to read in BBA-Biomembranes.

This story has been covered by CTV News in "Huge therapeutic potential': University of Sask. researchers make progress on stroke treatment" and a video interview can be watched on the CTV News Regina website. A podcast is also available hosted by Gormley on Demand and a news article on CBC News: "Potential treatment for stroke, brain injury studied with help from Saskatoon's synchrotron

Similar stories

Blood bank storage can reduce ability of transfusions to treat anaemia

New research from the Swietach Group in collaboration with NHS Blood and Transplant has demonstrated that the process of storing blood in blood banks can negatively impact the function of red blood cells and consequently may reduce the effectiveness of blood transfusions, a treatment commonly used to combat anaemia.

Overlapping second messengers increase dynamic control of physiological responses

New research from the Parekh and Zaccolo groups reveals that a prototypical anchoring protein, known to be responsible for regulating several important physiological processes, also orchestrates the formation of two important universal second messengers.

Feeling tired? Here’s how the brain’s ‘hourglass’ controls your need for sleep – new research

New article on The Conversation website written by Dr Lukas Krone, Associate Professor Vladyslav Vyazovskiy and Professor Zoltán Molnár.

Scientists Decipher How NeuroImmune Interactions Burn Deep Fat

A pioneering collaborative mouse study from an international team of researchers including DPAG's Associate Professor Ana Domingos published in Nature offers new therapeutic avenues for reducing visceral fat stores, which have been associated with cardiovascular disease and multiple types of cancer.

Study set to detect hidden lung damage in Long Covid Patients

Following the successful identification of long-term previously invisible lung damage in post-Covid patients, a large NIHR grant will enable a University of Oxford team including DPAG's Dr James Grist to continue this crucial work to shed light on why people with confirmed Long Covid continue to experience breathlessness following recovery from Covid-19.